Clinical

CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release – New drug to repair damaged skin and reduce skin cancer risk

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

Media Release - Second Afamelanotide Formulation

PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

PRÉNUMBRA® – New Liquid Afamelanotide Presentation

EXECUTIVE SUMMARY• PRÉNUMBRA® non-solid dosage form of afamelanotide• Active life-cycle management of...

Read More
CLINUVEL
Posted by CLINUVEL
February 10, 2020

Request for FDA Guidance Meeting SCENESSE® in Vitiligo

CLINUVEL requests Type C Guidance meeting to progress the clinical program in...

Read More
CLINUVEL
Posted by CLINUVEL
February 3, 2020

Australian TGA commences SCENESSE® review

EXECUTIVE SUMMARY SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare...

Read More